Pivampicillin compared with erythromycin for treating
women with genital *Chlamydia trachomatis* infection

MARIE CRAMERS,* PIA KASPERSEN,† ELLIS FROM,* BIRGER R MØLLER†

*From the Departments of* *Dermatology and Venereology,* †*Obstetrics and Gynaecology,* University Hospital,
Aarhus, Denmark

**SUMMARY** In a randomised single blind study, pivampicillin was compared with erythromycin in
women with urogenital *Chlamydia trachomatis* infections. The pivampicillin dosage was 700 mg twice
a day and the erythromycin dosage 500 mg twice a day for seven days. Follow up took place on days 7
and 14 after the start of treatment.

All 26 women treated with pivampicillin were culture negative for chlamydiae at the first and
second follow up visits. All 23 women who received erythromycin were culture negative at the first
follow up visit, but one was culture positive at the second follow up visit.

Gastrointestinal side effects were recorded in five patients receiving pivampicillin and in nine
receiving erythromycin. Two patients receiving erythromycin were withdrawn from treatment
because of gastrointestinal disturbances, compared with none receiving pivampicillin.

*Chlamydia trachomatis* is probably the most common
sexually transmitted organism in the Western World,
and it causes cervicitis, urethritis, endometritis,
endosalpingitis, periappendicitis, and perihepatitis in
women.¹ Tetracyclines or erythromycin are recom-
manded to treat genital chlamydial infections, whereas
penicillins have been regarded as ineffective.²

In a preliminary publication we reported excellent
results of 10 day treatment with pivampicillin in
eradicating *C trachomatis* from the genital tracts of
women.³ That study, however, did not evaluate the
optimum dose and did not compare the efficacy of
treatment with that of generally accepted first line
drugs. In the study reported here we therefore com-
pared the effect of pivampicillin with that of eryth-
romycin in treating genital chlamydial infection in
women.

**Patients and methods**

**Patients**
We included in a randomised single blind (investigator
blinded) study 49 women from whose cervixes or
urethras, or both, *C trachomatis* had been cultured,
but who were culture negative for *Neisseria gonorr-
hoae.*

**Study design**
At the first visit of each patient to the department of
venereology of this hospital, urethral and cervical
material was taken for culture for *C trachomatis* and
*N gonorrhoeae.* We investigated patients who were
culture positive for chlamydiae but negative for
gonococci. Each patient received either pivampicillin
700 mg twice a day for seven days or erythromycin
stearate 500 mg twice a day for seven days, to be taken
immediately before meals. We asked patients to
abstain from sexual intercourse during the investiga-
tion. Urethral and cervical specimens were cultured
for *C trachomatis* at follow up on days 7 and 14 after
the start of treatment.

We excluded patients who had taken antibiotics in
the preceding month or who were allergic to penicillin
or erythromycin. We traced and treated all sexual
contacts.

**Results**
Pivampicillin was given to 26 women (mean age 21
(range 18 to 27)), and erythromycin to 23 women
(mean age 21 (range 18 to 26)). No bacteriological
Doses of amoxycillin (all patients were culture negative for *C. trachomatis*) at the first and second follow up visits, except two who did not attend for the second follow up. All 23 treated with erythromycin were culture negative for chlamydiae at the first follow up, but one woman was culture positive at the second follow up. She denied the possibility of reinfection.

Gastrointestinal side effects were recorded in five patients receiving pivampicillin and in nine receiving erythromycin. Two receiving erythromycin were withdrawn after a few days of treatment because of gastrointestinal disturbances, whereas all patients receiving pivampicillin completed the treatment. One patient treated with pivampicillin developed a maculopapular eruption of the skin three to four days after the end of treatment; no skin eruptions were observed in those receiving erythromycin.

**Discussion**

Antibiotics may be classified as being in one of three groups according to their in vitro activity against *C. trachomatis*: those with high activity (minimum inhibitory concentrations (MIC) less than 0.06 mg/l) include tetracycline and erythromycin, those with intermediate activity (MIC 0.25–4.0 mg/l) include pivampicillin, and those with low activity (MIC 64–256 mg/l) include trimethoprim and metronidazole.

The study design included a second follow up examination seven days after the end of treatment. A longer period of surveillance would probably have shown more treatment failures. The increased risk of reinfection during a longer follow up period, however, makes it difficult to distinguish whether a positive chlamydial culture is a result of reinfection or of treatment failure.

Erythromycin is a well established drug in treating urogenital chlamydial infection. In different studies, doses of 500 mg twice daily for 10 to 14 days resulted in incidences of reisolation of 0% to 22%. Amoxycillin 1.5 g a day for 10 days given to nine pregnant women with chlamydial infection resulted in reisolation from three women after delivery.

Alexander and Harrison, however, reported that seven day treatment with 1.5 g amoxycillin was effective in eradicating cervical chlamydial infection.

Pivampicillin as an alternative to first line drugs (erythromycin and tetracyclines) for treating chlamydial infections was studied by Johannisson et al., who found that five of 22 men with urogenital chlamydial infections were culture negative after treatment with pivampicillin for seven days, whereas eight complained of persistent symptoms. Similarly, Hagdrup et al. found that only seven of 14 chlamydia positive patients were cured after treatment with 500 mg pivampicillin three times a day for seven days. In contrast to those results, we found in a previous study as well as in our present investigation that pivampicillin is an acceptable alternative to erythromycin for treating uncomplicated lower genital tract infection caused by *C. trachomatis*.

**References**


